tiprankstipranks
Advertisement
Advertisement

KSPHF Stock Latest News

Kissei Pharmaceutical Reports No Treasury Share Purchases in July Under Ongoing Buyback Plan
Company AnnouncementsKissei Pharmaceutical Reports No Treasury Share Purchases in July Under Ongoing Buyback Plan
2d ago
Kissei Pharmaceutical Cuts Earnings Forecasts on Weak TAVNEOS Sales
PremiumCompany Announcements
Kissei Pharmaceutical Cuts Earnings Forecasts on Weak TAVNEOS Sales
8d ago
Kissei Pharmaceutical Highlights Q1 FY2026 Results and R&D Pipeline Focus
PremiumCompany Announcements
Kissei Pharmaceutical Highlights Q1 FY2026 Results and R&D Pipeline Focus
8d ago
Kissei Pharmaceutical Posts Mixed Q1 Results, Lifts Dividends but Cuts FY2027 Outlook
PremiumCompany Announcements
Kissei Pharmaceutical Posts Mixed Q1 Results, Lifts Dividends but Cuts FY2027 Outlook
8d ago
Kissei Pharmaceutical Co (KSPHF) Q1 Earnings Cheat Sheet
PremiumPre-Earnings
Kissei Pharmaceutical Co (KSPHF) Q1 Earnings Cheat Sheet
10d ago
Kissei Pharmaceutical Completes Treasury Share Disposal for Executive Restricted Stock
PremiumCompany AnnouncementsKissei Pharmaceutical Completes Treasury Share Disposal for Executive Restricted Stock
16d ago
Kissei Pharmaceutical Reports No Share Buybacks Yet Under 2026 Repurchase Program
Premium
Company Announcements
Kissei Pharmaceutical Reports No Share Buybacks Yet Under 2026 Repurchase Program
1M ago
Kissei Faces EU Setback as EMA Backs Revocation of TAVNEOS Authorization
Premium
Company Announcements
Kissei Faces EU Setback as EMA Backs Revocation of TAVNEOS Authorization
1M ago
Kissei Pharmaceutical Grants Restricted Stock to Board Members and Officers
PremiumCompany Announcements
Kissei Pharmaceutical Grants Restricted Stock to Board Members and Officers
2M ago
Kissei Pharmaceutical Sets Share Buyback Framework but Executes No Purchases in May
PremiumCompany Announcements
Kissei Pharmaceutical Sets Share Buyback Framework but Executes No Purchases in May
2M ago
Kissei Files Japan NDA for IDH1-Targeting AML Drug Olutasidenib
PremiumCompany Announcements
Kissei Files Japan NDA for IDH1-Targeting AML Drug Olutasidenib
2M ago
Kissei Tightens Safety Warnings on TAVNEOS After Serious Liver Risk Cases
PremiumCompany Announcements
Kissei Tightens Safety Warnings on TAVNEOS After Serious Liver Risk Cases
3M ago
Kissei Restricts TAVNEOS Use in Japan After Global Safety and Data Concerns
PremiumCompany AnnouncementsKissei Restricts TAVNEOS Use in Japan After Global Safety and Data Concerns
3M ago
Kissei Pharmaceutical Posts Record Sales as R&D Investment and Overseas Growth Intensify
Premium
Company Announcements
Kissei Pharmaceutical Posts Record Sales as R&D Investment and Overseas Growth Intensify
3M ago
Kissei Pharmaceutical Launches ¥6 Billion Share Buyback and Cancellation Plan
Premium
Company Announcements
Kissei Pharmaceutical Launches ¥6 Billion Share Buyback and Cancellation Plan
3M ago
Kissei Pharmaceutical Details FY2026 Results and R&D Pipeline in Supplementary Report
PremiumCompany Announcements
Kissei Pharmaceutical Details FY2026 Results and R&D Pipeline in Supplementary Report
3M ago
Kissei Pharmaceutical Swings to Operating Loss but Lifts Payouts and Eyes Profit Recovery
PremiumCompany Announcements
Kissei Pharmaceutical Swings to Operating Loss but Lifts Payouts and Eyes Profit Recovery
3M ago
KSPHF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
KSPHF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
Kissei sublicenses AML drug olutasidenib to Orient EuroPharma in Taiwan
PremiumCompany Announcements
Kissei sublicenses AML drug olutasidenib to Orient EuroPharma in Taiwan
3M ago
Kissei Pharmaceutical Names Research Chief Keiji Miyazawa as New President and COO
PremiumCompany AnnouncementsKissei Pharmaceutical Names Research Chief Keiji Miyazawa as New President and COO
4M ago
Kissei Launches Yselty in Japan, Expanding Global Uterine Fibroid Treatment Portfolio
Premium
Company Announcements
Kissei Launches Yselty in Japan, Expanding Global Uterine Fibroid Treatment Portfolio
5M ago
Kissei Pharmaceutical to Allocate ¥2.4 Billion in Treasury Shares to Employee Shareholding Plan
Premium
Company Announcements
Kissei Pharmaceutical to Allocate ¥2.4 Billion in Treasury Shares to Employee Shareholding Plan
5M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >